Goodwin today announced that Paul Rosie has joined the firm’s Life Sciences group as a partner in the Boston office.
“We’re pleased to have Paul rejoin our Life Sciences team at Goodwin,” said Mitch Bloom, partner and co-chair of the Life Sciences group at Goodwin. “His expertise, particularly in medtech, will continue to enhance our ability to lead on complex matters and support clients throughout the corporate lifecycle. Paul brings strong relationships and a deep familiarity with the firm that will allow him to contribute from day one while strengthening an already exceptional bench.”
Paul advises high-growth companies and investors across the full corporate lifecycle, including venture capital financings, mergers and acquisitions, and capital markets transactions. He represents startups through later-stage companies, as well as venture capital funds, with a focus on the life sciences and technology industries. His experience spans pre-incorporation planning, equity financings, strategic transactions, exits, and a range of M&A deals and public offerings.
With more than 240 dedicated lawyers and patent agents across all major life sciences hubs in the US, Europe, and Asia, Goodwin works with life sciences companies throughout the corporate lifecycle – from startup and commercial-stage to maturity – as well as investors, banks, and others in the life sciences ecosystem. The firm understands the unique challenges life science companies face in securing funding, licensing and safeguarding intellectual property, establishing partnerships, bringing new products to market, opening new revenue streams, and protecting existing product lines. The team takes a multidisciplinary approach to address clients’ challenges, drawing on deep expertise across industries – such as technology, healthcare, real estate, and private equity – as well as the full spectrum of relevant practices.